Displaying drugs 351 - 375 of 407 in total
| Name | Weight | Structure | Desription | Categories |
|---|---|---|---|---|
| Fremanezumab | 148000.0 |  | A humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines. | Calcitonin Gene-Related Peptide (CGRP) Antagonists |
| Teprotumumab | 148000.0 |  | A fully human monoclonal antibody directed against insulin-like growth factor-1 receptor for the treatment of thyroid eye disease. | Selective Immunosuppressants |
| Ravulizumab | 148000.0 C6430H9888N1696O2028S48 | | A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. | Selective Immunosuppressants |
| Isatuximab | 148000.0 | | A chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies. | CD38 (Clusters of Differentiation 38) inhibitors |
| Retifanlimab | 148000.0 C6456H9934N1702O2032S46 | | A PD-1–blocking antibody indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. | PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Amivantamab | 148000.0 | | An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation. | Antineoplastic Agents, Immunological |
| Relatlimab | 148000.0 C6472H9940O2026N1704S38 | | A monoclonal antibody targeted against LAG-3 which is used in combination with nivolumab for the treatment of unresectable or metastatic melanoma. | Immune Checkpoint Inhibitors |
| Rozanolixizumab | 148000.0 | | A humanized monoclonal antibody targeting the human neonatal Fc receptor (FcRn) used to treat generalized myasthenia gravis. | Immunosuppressive Agents |
| Elotuzumab | 148100.0 C6476H9982N1714O2016S42 |  | An antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents. | Antibodies, Monoclonal |
| Bezlotoxumab | 148200.0 C6464H9974N1726O2014S46 | | A monoclonal antibody used to reduce the recurrence of Clostridium difficile infections. | Antibacterial monoclonal antibodies / Specific Immunoglobulins |
| Elranatamab | 148500.0 C6440H9958N1738O2010S49 | | A bispecific antibody used to treat adults with relapsed or refractory multiple myeloma. | Amino Acids, Peptides, and Proteins / Antibodies, Monoclonal / Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager / Bispecific Monoclonal Antibodies / Blood Proteins / Immunoglobulins / Proteins / Serum Globulins |
| Ustekinumab | 148600.0 |  | A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. | Interleukin Inhibitors |
| Omalizumab | 149000.0 |  | A monoclonal anti-immunoglobulin E (IgE) antibody used to treat asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy. | Anti-Allergic Agents / Anti-Asthmatic Agents / Anti-IgE / Antibodies, Monoclonal, Humanized |
| Natalizumab | 149000.0 |  | A monoclonal anti-integrin antibody used to treat Crohn's disease or multiple sclerosis. | Selective Immunosuppressants |
| Bevacizumab | 149000.0 C6538H10034N1716O2033S44 |  | A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. | Antibodies, Monoclonal / Antineovascularisation Agents / VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors |
| Mepolizumab | 149000.0 |  | A fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. | Interleukin-5 Antagonist |
| Pembrolizumab | 149000.0 C6504H10004N1716O2036S46 |  | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. | Antibodies, Monoclonal / PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| Tremelimumab | 149000.0 C6500H9974N1726O2026S52 | | An anti-CTLA-4 antibody used to treat unresectable hepatocellular carcinoma in combination with durvalumab. | Antineoplastic Agents |
| Inebilizumab | 149000.0 | | A humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD). | Selective Immunosuppressants |
| Risankizumab | 149000.0 C6476H9992N1720O2016S44 | | An interleukin-23 antagonist used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults. | Interleukin Inhibitors |
| Sotrovimab | 149000.0 | | A monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization. | Antiviral Agents / Antiviral monoclonal antibodies |
| Tixagevimab | 149000.0 C6488H10034N1746O2038S50 | | An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. | Antiviral monoclonal antibodies |
| Faricimab | 149000.0 C6506H9968N1724O1026S45 | | An IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema. | Angiogenesis Inhibitors / Antineovascularisation Agents |
| Epcoritamab | 149000.0 C6471H9999N1735O2007S44 | | A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. | Amino Acids, Peptides, and Proteins / Antibodies, Monoclonal / Antibodies, Monoclonal, Humanized / Antineoplastic Agents / Bispecific Monoclonal Antibodies / Blood Proteins / Cancer immunotherapy / CD20-directed Antibody Interactions / CD3-directed Antibody Interactions / Immunoglobulins / Immunotherapy / Increased Cytokine Production / Proteins / Serum Globulins |
| Teplizumab | 150000.0 C6462H9938N1738O2022S46 |  | A CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes in patients with Stage 2 type 1 diabetes. | Alimentary Tract and Metabolism / Amino Acids, Peptides, and Proteins / Antibodies / Antibodies, Monoclonal / Antibodies, Monoclonal, Humanized / Blood Proteins / CD3-directed Antibody / CD3-directed Antibody Interactions / Drugs Used in Diabetes / Globulins / Immunoglobulins / Immunoproteins / Proteins / Serum Globulins |
Displaying drugs 351 - 375 of 407 in total